Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder

Phase 3CompletedNCT00195598

Wyeth is now a wholly owned subsidiary of Pfizer70 enrolled

Overview

The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Panic Disorders

Interventions

VENLAFAXINEDRUG

ParoxetineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1. * Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit. * Provide a written informed consent Exclusion Criteria: * Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine * Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine. * Psychopharmacologic drugs within 14 days of study day 1

Locations (4)

Unnamed facility

Jundiaí, São Paulo, Brazil

Unnamed facility

Santo André, São Paulo, Brazil

Unnamed facility

São Paulo, São Paulo, Brazil

Unnamed facility

São Paulo, São Paulo, Brazil

Outcomes

Primary Outcomes

To evaluate the improvement of social function following therapy with Venlafaxine extended release (XR)in the Treatment of Panic Disorder in comparison to Paroxetine.

Secondary Outcomes

Obtain the tolerability of using Venlafaxine extended release (XR) in the treatment of Panic Disorder in comparison to Paroxetine.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.